NCT03988790

Evaluation of the Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled Air

Evaluation of Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled Air

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Hopital Foch · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the change in the composition of Volatil Organic Compounds (VOC) in patients treated by monoclonal antibody for severe asthma.

Detailed description

At least one in two patients treated by monoclonal antibody for severe asthma doesn't have satisfying result after 6 months of treatment. The evaluation of the answer, and even better the answer prediction, are fundamental issues for medico-economic plan as part of these innovative therapeutics. The interest of the use of VOC as diagnostic or prognostic tool in patients with tumoral thoracic pathology or bronchial or pulmonary vascular diseases has been demonstrated. VOC analysis will be performed using two different techniques: electronic nose and masse spectrometry. At each visit, in addition to the usual assessment, patients will have two non-invasives collections of exhaled air, one for electronic nose analysis and one for masse spectrometry analysis.

Conditions

• Asthma

Interventions

Type	Name	Description
DEVICE	VOC analysis	VOC analysis in exhaled air with e-noses and mass spectrometry.

Timeline

• Start date: 2018-12-04
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2019-06-17
• Last updated: 2021-02-16

Locations

1 site across 1 country: France